{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:47:11Z","timestamp":1787222831254,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["program grant 1016701"],"award-info":[{"award-number":["program grant 1016701"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Peter Doherty Early Career Fellowship 1089072"],"award-info":[{"award-number":["Peter Doherty Early Career Fellowship 1089072"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Career Development Fellowship 1090236"],"award-info":[{"award-number":["Career Development Fellowship 1090236"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["SCOR grant 7001-13"],"award-info":[{"award-number":["SCOR grant 7001-13"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["SCOR grant 7001-13"],"award-info":[{"award-number":["SCOR grant 7001-13"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","award":["Grants-in-Aid 1146518"],"award-info":[{"award-number":["Grants-in-Aid 1146518"]}],"id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,2,27]]},"DOI":"10.1038\/s41388-019-1122-x","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T19:02:53Z","timestamp":1574794973000},"page":"2009-2023","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma"],"prefix":"10.1038","volume":"39","author":[{"given":"Michael A.","family":"Dengler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis E.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Thijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahiru","family":"Gangoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco J.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry M.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"1122_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell."},{"key":"1122_CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","volume":"25","author":"JM Adams","year":"2018","unstructured":"Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27\u201336.","journal-title":"Cell Death Differ"},{"key":"1122_CR3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1122_CR4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","volume":"25","author":"J Montero","year":"2018","unstructured":"Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 2018;25:56\u201364.","journal-title":"Cell Death Differ"},{"key":"1122_CR5","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/emboj.2011.307","volume":"30","author":"A Strasser","year":"2011","unstructured":"Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30:3667\u201383.","journal-title":"EMBO J"},{"key":"1122_CR6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med."},{"key":"1122_CR7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase i study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488\u201396.","journal-title":"J Clin Oncol"},{"key":"1122_CR8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"N Engl J Med"},{"key":"1122_CR9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477\u201382.","journal-title":"Nature."},{"key":"1122_CR10","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8:1582\u201397.","journal-title":"Cancer Discov"},{"key":"1122_CR11","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8:1566\u201381.","journal-title":"Cancer Discov"},{"issue":"6","key":"1122_CR12","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41418-018-0183-7","volume":"26","author":"Georgia Greaves","year":"2018","unstructured":"Greaves G, Milani M, Butterworth M, Carter RJ, Byrne DP, Eyers PA, et al. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. Cell Death Differ. 2019;26:1037.","journal-title":"Cell Death & Differentiation"},{"key":"1122_CR13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/2040620717719616","volume":"8","author":"B Fakhri","year":"2017","unstructured":"Fakhri B, Kahl B. Current and emerging treatment options for mantle cell lymphoma. Ther Adv Hematol. 2017;8:223\u201334.","journal-title":"Ther Adv Hematol"},{"key":"1122_CR14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","volume":"125","author":"E Campo","year":"2015","unstructured":"Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125:48\u201355.","journal-title":"Blood."},{"key":"1122_CR15","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Investig. 2012;122:3416\u201323.","journal-title":"J Clin Investig"},{"key":"1122_CR16","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Bea","year":"2013","unstructured":"Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110:18250\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1122_CR17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.semcancer.2011.09.006","volume":"21","author":"JA Burger","year":"2011","unstructured":"Burger JA, Ford RJ. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol. 2011;21:308\u201312.","journal-title":"Semin Cancer Biol"},{"key":"1122_CR18","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.3275","volume":"6","author":"D Chiron","year":"2015","unstructured":"Chiron D, Dousset C, Brosseau C, Touzeau C, Maiga S, Moreau P, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6:8750\u20139.","journal-title":"Oncotarget."},{"key":"1122_CR19","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128:2808\u201318.","journal-title":"Blood."},{"key":"1122_CR20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826\u201333.","journal-title":"J Clin Oncol"},{"key":"1122_CR21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378:1211\u201323.","journal-title":"N Engl J Med"},{"key":"1122_CR22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/path.1254","volume":"199","author":"JD Khoury","year":"2003","unstructured":"Khoury JD, Medeiros LJ, Rassidakis GZ, McDonnell TJ, Abruzzo LV, Lai R. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol. 2003;199:90\u20137.","journal-title":"J Pathol."},{"key":"1122_CR23","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.552","volume":"5","author":"MA Dengler","year":"2014","unstructured":"Dengler MA, Weilbacher A, Gutekunst M, Staiger AM, Vohringer MC, Horn H, et al. Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles\u2019 heel in mantle cell lymphoma. Cell Death Dis. 2014;5:e1013.","journal-title":"Cell Death Dis"},{"key":"1122_CR24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"S Glaser","year":"2012","unstructured":"Glaser S, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26:120\u20135.","journal-title":"Genes Dev."},{"key":"1122_CR25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1101\/gad.232009.113","volume":"28","author":"GL Kelly","year":"2014","unstructured":"Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014;28:58\u201370.","journal-title":"Genes Dev."},{"issue":"14","key":"1122_CR26","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","volume":"25","author":"Dana Prukova","year":"2019","unstructured":"Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, et al. Co-targeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019;25:4455\u201365.","journal-title":"Clinical Cancer Research"},{"key":"1122_CR27","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","volume":"10","author":"BJ Aubrey","year":"2015","unstructured":"Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O\u2019Connor L, Milla L, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10:1422\u201332.","journal-title":"Cell Rep."},{"key":"1122_CR28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cancergencyto.2004.01.006","volume":"153","author":"C Rudolph","year":"2004","unstructured":"Rudolph C, Steinemann D, Von Neuhoff N, Gadzicki D, Ripperger T, Drexler HG, et al. Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519. Cancer Genet Cytogenet. 2004;153:144\u201350.","journal-title":"Cancer Genet Cytogenet"},{"key":"1122_CR29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","volume":"127","author":"HM Amin","year":"2003","unstructured":"Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O\u2019Connor SL, et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 2003;127:424\u201331.","journal-title":"Arch Pathol Lab Med"},{"key":"1122_CR30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.leukres.2005.11.013","volume":"30","author":"J Camps","year":"2006","unstructured":"Camps J, Salaverria I, Garcia MJ, Prat E, Bea S, Pole JC, et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res. 2006;30:923\u201334.","journal-title":"Leuk Res."},{"key":"1122_CR31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.leukres.2005.08.016","volume":"30","author":"CA Tucker","year":"2006","unstructured":"Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, et al. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 2006;30:449\u201357.","journal-title":"Leuk Res."},{"key":"1122_CR32","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127:3215\u201324.","journal-title":"Blood."},{"key":"1122_CR33","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","volume":"24","author":"H Tagawa","year":"2005","unstructured":"Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene. 2005;24:1348\u201358.","journal-title":"Oncogene."},{"key":"1122_CR34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","volume":"109","author":"C Mestre-Escorihuela","year":"2007","unstructured":"Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 2007;109:271\u201380.","journal-title":"Blood."},{"key":"1122_CR35","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra40.","journal-title":"Sci Transl Med"},{"key":"1122_CR36","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharm Res Perspect. 2015;3:e00149.","journal-title":"Pharm Res Perspect"},{"key":"1122_CR37","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1128\/AAC.35.6.1060","volume":"35","author":"MN Prichard","year":"1991","unstructured":"Prichard MN, Prichard LE, Baguley WA, Nassiri MR, Shipman C Jr. Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. Antimicrob Agents Chemother. 1991;35:1060\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1122_CR38","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0066-7","volume":"8","author":"S Huang","year":"2018","unstructured":"Huang S, Jiang C, Zhang H, Bell T, Guo H, Liu Y, et al. The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J. 2018;8:33.","journal-title":"Blood Cancer J"},{"key":"1122_CR39","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","volume":"166","author":"J Ma","year":"2014","unstructured":"Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, et al. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol. 2014;166:849\u201361.","journal-title":"Br J Haematol"},{"key":"1122_CR40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393\u2013403.","journal-title":"Mol Cell."},{"key":"1122_CR41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Moore Vdel G, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351\u201365.","journal-title":"Cancer Cell."},{"key":"1122_CR42","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","volume":"115","author":"D Yecies","year":"2010","unstructured":"Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115:3304\u201313.","journal-title":"Blood."},{"key":"1122_CR43","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1038\/sj.onc.1210363","volume":"26","author":"G Brien","year":"2007","unstructured":"Brien G, Trescol-Biemont MC, Bonnefoy-Berard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene. 2007;26:5828\u201332.","journal-title":"Oncogene."},{"key":"1122_CR44","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-017-0157-6","volume":"9","author":"H Rauert-Wunderlich","year":"2018","unstructured":"Rauert-Wunderlich H, Rudelius M, Berberich I, Rosenwald A. CD40L mediated alternative NFkappaB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Cell Death Dis. 2018;9:86.","journal-title":"Cell Death Dis"},{"key":"1122_CR45","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.8096091","volume":"259","author":"SC Sun","year":"1993","unstructured":"Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-k B controls expression of inhibitor I k B a: evidence for an inducible autoregulatory pathway. Science. 1993;259:1912\u20135.","journal-title":"Science."},{"key":"1122_CR46","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","volume":"113","author":"AV Kurtova","year":"2009","unstructured":"Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604\u201313.","journal-title":"Blood."},{"key":"1122_CR47","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","volume":"19","author":"SN Willis","year":"2005","unstructured":"Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19:1294\u2013305.","journal-title":"Genes Dev."},{"key":"1122_CR48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25:119\u201329.","journal-title":"Nat Med."},{"issue":"4","key":"1122_CR49","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","volume":"33","author":"Donia M. Moujalled","year":"2018","unstructured":"Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2019;33:905\u201317.","journal-title":"Leukemia"},{"key":"1122_CR50","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","volume":"128","author":"JN Gong","year":"2016","unstructured":"Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016;128:1834\u201344.","journal-title":"Blood."},{"key":"1122_CR51","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/blood-2018-06-859405","volume":"132","author":"MS Brennan","year":"2018","unstructured":"Brennan MS, Chang C, Tai L, Lessene G, Strasser A, Dewson G, et al. Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood. 2018;132:1573\u201383.","journal-title":"Blood."},{"key":"1122_CR52","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104:e68\u201371.","journal-title":"Haematologica."},{"key":"1122_CR53","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","volume":"32","author":"TC Teh","year":"2018","unstructured":"Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia. 2018;32:303\u201312.","journal-title":"Leukemia."},{"key":"1122_CR54","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173\u201386.","journal-title":"Cell."},{"key":"1122_CR55","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","volume":"132","author":"P Gomez-Bougie","year":"2018","unstructured":"Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood. 2018;132:2656\u201369.","journal-title":"Blood."},{"key":"1122_CR56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/cdd.2011.158","volume":"19","author":"M Vogler","year":"2012","unstructured":"Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 2012;19:67\u201374.","journal-title":"Cell Death Differ"},{"key":"1122_CR57","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1365-2141.2003.04121.x","volume":"120","author":"B Nagy","year":"2003","unstructured":"Nagy B, Lundan T, Larramendy ML, Aalto Y, Zhu Y, Niini T, et al. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol. 2003;120:434\u201341.","journal-title":"Br J Haematol"},{"key":"1122_CR58","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","volume":"122","author":"BY Chang","year":"2013","unstructured":"Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122:2412\u201324.","journal-title":"Blood."},{"key":"1122_CR59","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1101\/gad.215871.113","volume":"27","author":"RL Thomas","year":"2013","unstructured":"Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27:1365\u201377.","journal-title":"Genes Dev."},{"key":"1122_CR60","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.22664","volume":"49","author":"B Vick","year":"2009","unstructured":"Vick B, Weber A, Urbanik T, Maass T, Teufel A, Krammer PH, et al. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology. 2009;49:627\u201336.","journal-title":"Hepatology."},{"key":"1122_CR61","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1523\/JNEUROSCI.4940-07.2008","volume":"28","author":"N Arbour","year":"2008","unstructured":"Arbour N, Vanderluit JL, Le Grand JN, Jahani-Asl A, Ruzhynsky VA, Cheung EC, et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J Neurosci. 2008;28:6068\u201378.","journal-title":"J Neurosci."},{"key":"1122_CR62","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nm.4505","volume":"24","author":"Z Good","year":"2018","unstructured":"Good Z, Sarno J, Jager A, Samusik N, Aghaeepour N, Simonds EF, et al. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nat Med. 2018;24:474\u201383.","journal-title":"Nat Med."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-1122-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-1122-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-1122-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:18:30Z","timestamp":1684617510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-019-1122-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,2,27]]}},"alternative-id":["1122"],"URL":"https:\/\/doi.org\/10.1038\/s41388-019-1122-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"20 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors are employees of the Walter and Eliza Hall Institute, who receive milestone and royalty payments related to venetoclax. MJH, GLK, and AWR have received research funding from Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}